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ABSTRACT 
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare genetically-
determined cardiac heart muscle disorder characterized by fibro-fatty 
replacement of the myocardium that causes heart failure and sudden cardiac 
death (SCD), predominantly in young males. The disease is often caused by 
mutations in genes encoding proteins of the desmosomal (cell-to-cell adhesion) 
complex, with a significant minority caused by mutations in non-desmosomal 
proteins. Existing treatment options are based on SCD prevention with the 
implantable cardioverter defibrillator and anti-heart failure medication. Heart 
transplantation may also be required and there is currently no cure. Several 
transgenic animal models have been developed to characterize the disease, 
assess its progression and determine the influence of potential environmental 
factors. Transgenic models are also very valuable for translational therapeutic 
approaches, to screen new treatment options that prevent and/or regress the 
disease. Here we review the available ARVC animal models reported to date, 
highlighting the most important pathophysiological findings and discussing the 
effect of treatments tested so far in this setting. We also describe gaps in current 





Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart 
muscle disease characterized by the progressive degeneration of cardiac 
myocytes, which are replaced by fibro-fatty tissue [32]. While the disease was 
initially named because of right ventricle (RV) involvement, it can also affect the 
left ventricle, in which case it is frequently termed arrhythmogenic 
cardiomyopathy (AC) [18, 49]. Patients with right ventricular arrhythmias and left 
ventricular involvement have a worse prognosis [40]. ARVC/AC is distinguished 
from dilated cardiomyopathy by its greater propensity towards arrhythmia [44, 
49]. However, current diagnostic ARVC criteria focus on the RV and non-classical 
disease patterns could still be underdiagnosed [32]. ARVC/D can be a 
devastating disease given the fact that the first symptom is often sudden cardiac 
death (SCD). Clinical manifestations, such as dizziness, heart palpitations and 
SCD appear in young men from an average age of 31 [40]. In the early “hidden 
phase” of the disease, patients are asymptomatic even if they are at high risk for 
ventricular arrhythmia and SCD. Pathologically, the disease is characterized by 
myocardial atrophy, fibro-fatty replacement and chamber dilation [33]. 
ARVC is a significant cause of premature SCD in young people and athletes, 
accounting for more than 10% of overall cases in these individuals [10, 51]. 
Current treatment options for ARVC include the implantable cardioverter 
defibrillator (ICD) and ventricular arrhythmias catheter ablation to prevent SCD, 
as well as commonly used anti-heart failure drugs to treat ventricular dysfunction 
and heart failure. These measures do not completely prevent ARVC progression 
and treatment focusses on slowing disease progression, decreasing the burden 
of arrhythmias with anti-arrhythmic drugs and preventing SCD with ICDs. In case 
of end-stage heart failure or an arrhythmia storm, heart transplantation is 
commonly considered. Furthermore, it has been observed that physical activity 
increases the risk of SCD in patients with ARVC and restriction from strenuous 
exercise is recommended for affected individuals and healthy mutation carriers 
in order to delay the progression of disease [34]. Because early molecular and 
cellular events underlying ARVC onset as well as its progression remain largely 
unknown, current therapeutic options are mostly palliative (Figure 1). Moreover, 
early manifestations of ARVC are frequently subclinical, escaping detection by 
conventional imaging and surface electrocardiogram (ECG). For these reasons, 
animal models are invaluable to help gain a deeper understanding of the 
underlying pathophysiological mechanisms of ARVC and to assist in the 
development of potential therapies that could ultimately be translated into clinical 
practice.  
Up to 60% of ARVC cases are attributed to mutations in genes encoding proteins 
of the desmosomal complex [25], an anchoring structure crucial for cell-to-cell 
adhesion, with the remaining cases caused by mutations encoding proteins 
beyond the desmosome. Desmosomes are complex structures formed by 
proteins, and function to bind myocardial cells to each other. In the heart, 
desmosomes are composed of five proteins (Figure 2) and are indispensable for 
electrical conduction and mechanical contraction in myocardial cells [42]. To 
date, human genetic studies of ARVC have identified 12 independent loci and 8 
dominant ARVC-causing genes. Different genotypes of ARVC are classified into 
several groups based on the causative mutated gene involved (Table 1) [42].  
This review focuses on the currently available animal, mostly mouse, models 
employed to study ARVC, and the pathophysiological mechanisms that have 
been reported to date. Based on the results obtained using a variety of transgenic 
approaches, we discuss the utility and suitability of different models of ARVC in 
translational studies, including the role of exercise and new therapeutic targets. 
 
 
Desmosomal ARVC models  
The genetic basis of ARVC is largely attributed to mutations in the desmosomal 
complex. Desmosomes are multiprotein structures of the cell membrane that act 
as specialized cell-cell junctions, providing structural and functional integrity to 
adjacent cells. They are particularly abundant in epithelial cells and 
cardiomyocytes [20]. Desmosomes are composed of transmembrane 
desmosomal cadherins (desmocollin 2 and desmoglein 2), armadillo proteins 
(junctional plakoglobin [-catenin] and plakophilin 2) and the centralized plakin 
protein, desmoplakin, which links the junctional complex to the intermediate 
filament, desmin, to maintain the mechanical integrity of cardiac muscle [42] 
(Figure 2). They differ from other intercellular junctions since they resist 
mechanical stress, adopting a strongly adhesive state. In desmosomal ARVC, 
desmosomal instability cannot withstand the unceasing mechanical stress in 
contracting cardiomyocytes, ultimately leading to cardiac dysfunction and cell 
death.  
The main function of desmosomes is thus to mechanically link tissues that 
experience mechanical stress. In many diseases related to the desmosome, 
however, it is difficult to ascribe all aspects of the phenotype to defective cell 
adhesion. Indeed, it is often not clear whether the symptoms that occur in human 
diseases that target desmosomes arise primarily from loss of adhesion or from 
modulation of signaling pathways involving desmosomes [19]. This is because 
desmosomes also participate in intracellular signaling networks. Desmosomal 
cadherins are involved in regulating crucial cellular processes such as 
proliferation, differentiation and morphogenesis. Although the mechanisms 
remain elusive, they may achieve this by regulating the availability of signaling 
molecules. As we will discuss later, plakoglobin, a major component of 
desmosomes, is closely related to -catenin and has a role in Wnt/-catenin 
signaling [17] (Figure 2). Desmosomes have also a critical role in embryonic 
development. Accordingly, homozygous null mutations in the genes encoding the 
desmosomal complex are embryonic lethal in mice [16, 17, 23, 46], but 
heterozygous null alleles for plakoglobin or plakophilin 2 cause little, if any, 
phenotypic changes [17, 46, 54]. Further research is needed to define the 
signaling capacity of desmosomes and to specify the downstream consequences 
of their signaling activity.  
 
Desmoplakin 
Desmoplakin, encoded by the DSP gene, is a member of the plakin family of coil-
coiled proteins that lacks a transmembrane domain and resides in the 
cytoplasmic surface of the desmosome. It facilitates the association of the 
desmosome with intermediate filaments, for desmosome assembly, cytoskeletal 
linkage and embryonic development. Mutations in DSP can lead to ARVC in an 
autosomal dominant manner or to a more complex syndrome, called Carvajal 
syndrome, when inherited in an autosomal recessive manner. Carvajal patients 
present dilated cardiomyopathy, woolly hair and palmoplantar keratoderma [5]. 
No animal model is currently available for this syndrome. 
Systemic null mutations in DSP in mouse embryos lead to early lethality at 
embryonic day 6.5 [16]. In heterozygous mice expressing a point mutation or a 
disrupted form of DSP [17, 54], plakoglobin is mislocalized to the nucleus, where 
it suppresses Wnt/-catenin canonical signaling. Inhibition of this pathway, a key 
regulator of the transcriptional switch from myogenesis to adipogenesis, leads to 
enhanced adipogenesis, fibrogenesis, and myocyte apoptosis, all of which are 
characteristic features of human ARVC. Moreover, reduced expression of DSP 
has been shown to cause mislocalisation of the gap junctional protein connexin 
43 in a cardiomyocyte-specific DSP haploinsufficiency mouse model [21], which 
presents significant alterations in conduction-repolarisation kinetics that 
precedes morphological changes detectable on conventional cardiac imaging. In 
cardiomyocyte-specific DSP-knockout mice (DSP-cKO) [31], which models a 
biventricular form of human ARVC, mutant hearts harbour defects in desmosomal 
structural integrity, a primary causes of dysfunction in this model. Furthermore, 
connexin 40 expression is dramatically downregulated in cardiomyocytes of the 
ventricular conduction system in DSP-cKO hearts, illustrating the importance for 
anchoring desmosomes in cardiac conduction system. Moreover, the Wnt/-
catenin signaling pathway is unimpaired and the mechanism by which the 
adipogenesis switch occurs is different to that of the models described above. 
The authors of this study posit that a dose-dependent loss of DSP would lead to 
downregulation of connexin 43, resulting in conduction abnormalities prior to the 
molecular dissociation of the mechanical junction complex and preceding the 
fibro-fatty manifestation observed in ARVC.  
These models assign a central role to DSP in the desmosomal structure, and 
while it lacks a transmembrane domain, it is essential to anchor desmosomal 
proteins and to provide structural integrity to the cell membrane 
 
Plakophilin 2 
Plakophilin 2 (PKP2) is an armadillo-related protein located in the outer dense 
plaque of desmosomes that links desmosomal cadherins with DSP and 
intermediate filaments. PKP2 facilitates lateral interaction of the desmosomal 
cadherins desmocollin and desmoglein using its N-terminal domain. In humans, 
autosomal dominant mutations in PKP2 are the most common genetic cause of 
ARVC, contributing to approximately 70% of familial ARVC cases [52].  
Germline PKP2 deficiency in mice results in heart rupture during cardiac 
development [23]. PKP2 deficiency provokes a reduction in the association of the 
cardiac junctional plaques with DSP, plakoglobin and desmosomal cadherins, 
which is consistent with the reduced architectural stability of the intercalated discs 
(IDs) in ARVC9. Nevertheless, several elements of the ID remain intact, for 
example, several armadillo proteins such as -catenin and plakoglobin remain in 
their correct locations. This indicates that their binding to other plaque 
components is sufficient for their junctional integration. Considering that the 
developing embryonic heart is particularly vulnerable to diverse forms of 
weakening of cardiomyocyte adhesion, these findings lead to the conclusion that 
PKP2 is a key organizer of cardiac architecture during embryogenesis. The fact 
that PKP2 is the only plakophilin present in cardiac adhering junctions may 
explain this extraordinary sensitivity in mutant hearts. 
Further studies performed on PKP2 heterozygous (PKP2+/-) mice revealed 
myocyte sodium current defects, suggesting cross-talk between the desmosome 
and sodium channel complex and pointing to the potential contribution of sodium 
current dysfunction to arrhythmias. In contrast to other animal models of 
desmosomal deficiency, PKP2+/- mice do not develop overt structural disease; 
PKP2+/- hearts show ultrastructural, but not histological or gross anatomical 
differences when compared with wild-type (WT) littermates [7]. Although this 
could be considered a weakness of the model, it nonetheless enables the study 
of arrhythmogenic substrates in the absence of structural involvement. 
 
Desmoglein 2 and Desmocollin 2 
The desmosomal cadherins –desmogleins and democollins– are single 
transmembrane glycoproteins that bridge the space between adjacent cardiac or 
epithelial cells. They mediate Ca2+-dependent homophilic interactions between 
the extracellular regions of desmosomal cadherins, providing additional support 
for their adhesive functions. The intracellular domain of desmosomal cadherins 
binds to two proteins of the armadillo family, plakoglobin and plakophilin, forming 
an indirect link to desmoplakin and desmin. 
Inactivation of the DSG2 gene by homologous recombination in embryonic stem 
cells to generate a DSG2-/- knock-out mouse model results in embryonic lethality  
[14], indicating that DSG2 has essential functions for early embryo development. 
To circumvent the embryonic lethality of DSG2-/- mice, which hinders the 
characterization of the role of DSG2 in the post-natal heart, Pilichou et al 
generated a transgenic mice with cardiac overexpression of the N271S mutation 
of DSG2, equivalent to N266S in humans, which recapitulates key clinical 
features of ARVC10 including spontaneous ventricular arrhythmias and sudden 
death, cardiac dysfunction, biventricular dilatation and ventricular aneurysms. 
The birth of viable animals provided evidence that DSG2 is not essential for 
growth and function of the heart during embryogenesis. This is an important 
finding as desmosomal cadherins are major components of the desmosome [42]. 
In this model, myocyte necrosis is considered the central initiator of myocardial 
dystrophy, which would subsequently trigger an inflammatory response and 
massive calcification within the myocardium, followed by injury repair with 
replacement of dead cardiomyocytes by fibrous tissue [43]. Unfortunately, the 
model does not exhibit fatty infiltration, a characteristic finding in human ARVC. 
Proposed explanations for the absence of fat deposition in mice transgenic for 
mutant DSG2 as well as other models include the difference between species 
and the fact that the mouse heart does not show evidence of epicardial fat. This 
feature is different from the human heart, where a physiological amount of fatty 
tissue can always be found in the subepicardium. 
From further study of the N271S transgenic mouse, the same authors found an 
in vivo interaction between DSG2 and the Na(V)1.5 sodium channel protein, 
indicating that conduction disturbances and electrical instability would be early 
events of ARVC disease, before structural changes to the myocardium [45]. This 
analysis, along with the study of a cardiomyocyte-specific DSG2 knock-out model 
[27], also showed intercellular space widening at the level of the ID 
(desmosomes/adherens junctions) and a concomitant reduction in action 
potential, indicating compromised adhesion of cardiomyocytes. These data 
strongly support an important adhesive role for DSG2.  
In contrast to desmoglein 2, almost no functional knockout models are available 
for desmocollin 2 (DSC2). Nevertheless, a very recent study provided evidence 
that the microRNA, miR-130a, targets DSC2 [37]. Although this mouse model 
does not directly target DSC2, transgenic mice overexpressing miR-130a 
presented an 80% reduction in the protein expression of DSC2 in the myocardium 
together with right ventricular dilation. Moreover, surface ECG revealed 
spontaneous premature ventricular complexes, and histological examination 
showed fibrosis and lipid accumulation within both ventricles. Thus, miR-130a 
overexpression results in a disease phenotype characteristic of ARVC11. In 
another recent study, Brodehl et al. developed a transgenic mouse model 
overexpressing DSC2 specifically in cardiac myocytes to determine its potential 
contribution to cardiomyopathy and intercellular adhesion pathology [6]. 
Transgenic mice developed a severe cardiac biventricular dysfunction, 
accompanied by necrosis, calcification and early up-regulation of inflammatory 
and fibrotic remodeling pathways. However, these mice did not present 
ventricular arrhythmias or SCD. The expression of endogenous desmosomal 
proteins including DSG2, plakoglobin and DSP was downregulated in mutant 
mice only in fibrotic areas, indicating a local remodeling process due to the 
replacement of cardiomyocytes rather than a global downregulation of 
endogenous desmosomal genes. This remodeling alters cell-to-cell adhesion, a 
process that needs to be fine-tuned in cardiomyocytes for their proper 
contraction. 
Overall, results from these mouse models reveal that the cadherins desmoglein 
2 and desmocollin 2 are not functionally interchangeable. Even though 
desmosomal proteins remain efficiently recruited to and associated with the ID in 
the absence of DSG2, the desmosomal structure is not maintained. Conversely, 
desmosomal proteins are downregulated in the absence of DSC2.  
 
Plakoglobin 
Plakoglobin (-catenin, JUP) is a member of the armadillo family of proteins, 
which is characterized by domains with tandem arm repeats that form a distinct 
three-dimensional structure allowing them to interact with distinct partners. JUP 
can be found in the desmosomal plaque and in intermediate junctions, as well as 
freely diffusible in the cytosol. In desmosomes, JUP is involved in the anchorage 
of cytoskeletal filaments to specific cadherins. JUP is an essential component of 
cardiac but not of epithelial desmosomes during embryonic development and 
mutations in the protein lead to a highly penetrant form of ARVC, ARVC12. JUP 
and the closely related homologous protein -catenin share 88% amino acid 
identity and functionally complete for common protein binding partners [29]. 
Homozygous JUP mutant mice die from embryonic day 10.5 onwards due to 
severe heart defects [3, 46], although some can survive until late gestation and 
die around birth [3] likely due to partially compensatory mechanisms between 
JUP and β-catenin. Enhanced adipogenesis due to suppression of Wnt/-catenin 
signaling has been demonstrated in a mouse model of truncated JUP [9]. 
To overcome embryonic lethality in homozygous JUP mutant mice, Li et al. [29] 
generated a cardio-restricted conditional JUP KO model using Cre/loxP 
technology. Knockout mice developed cardiomyopathy 5 months after 
recombination at 6–8 weeks of age, and presented progressive loss of cardiac 
myocytes, extensive inflammatory infiltration, fibrous tissue replacement, and 
cardiac dysfunction, essentially mirroring the phenotype of ARVC patients. 
Nonetheless, no spontaneous or induced cardiac arrhythmias were detected in 
these mice, and more than 50% of JUP cardiac-deficient mice survived 17 
months after recombination. Given that ARVC predominantly affects the young, 
ablating JUP at embryonic or early postnatal stages may be more physiologically 
informative. 
Overall, these models indicate that the loss of JUP from the desmosome cannot 
be compensated by -catenin, leading to an altered desmosomal structure. 
Moreover, JUP is able to antagonize -catenin signaling in the heart. 
Although autosomal dominant is the most common inherited pattern in ARVC, a 
recessive form of JUP deficiency that presents with ARVC and a cutaneous 
phenotype has also been reported. Naxos disease, named after the Greek island 
of Naxos where the first cases were described, is caused by a frameshift mutation 
in JUP, resulting in premature termination and expression of a truncated protein 
[38]. Phenotypically, Naxos disease is characterized by woolly hair, which 
appears from birth, palmoplantar keratoderma, which develops during the first 
year of life, and cardiomyopathy, which is clinically manifested by adolescence 
with 100% penetrance. Several mouse models have successfully reproduced 
Naxos disease, showing defects in embryonic skin architecture and extreme 
sensitivity to mechanical stress [3, 4, 56]. Unfortunately, mutant mice die during 
late embryogenesis or soon after birth, indicating that there could be differences 
in the mutant JUP expression levels between human patients and mouse models, 
or divergent requirements for the amount of JUP in the two species. 
 
Non-desmosomal ARVC models  
While the non-desmosomal ARVC subtype is less common, several animal 
models have been developed to reproduce different aspects of ARVC 
pathogenesis. Despite the fact that some of the mutations have not yet been 
found in human patients with ARVC, the models recapitulate most of the features 
of the human disease and could improve our understanding of the mechanisms 
involved and also help in the development of new therapies. 
  
Laminin receptor 1 (LAMR1)  
 
Mutations in the nuclear protein laminin receptor 1 (LAMR1) have not been 
detected in humans; however, a serendipitous mouse model carrying a LAMR1 
mutation induced by a transcribed intron-processed retroposon was discovered 
to present an ARVC phenotype. Phenotype penetrance was almost 100% and 
macroscopic examination of the heart at 8 weeks of age showed massive fibrosis 
limited to the RV [1]. Histological analysis revealed macrophage infiltration 
between fibrotic and viable tissue, but again no fat infiltration was reported. 
Electrocardiographic monitoring failed to reveal ventricular tachyarrhythmias, but 
a prolonged QRS duration was detected by ECG, indicating a greater 
susceptibility to arrhythmia. These findings were subsequently confirmed in two 
independent transgenic mouse lines that expressed mutant LAMR1 [1]. 
 
Regulators of desmosomes. 
It has been recently observed that deficiency of the inhibitor of apoptosis-
stimulating protein p53 (iASPP) caused by spontaneous mutation is associated 
with a lethal autosomal recessive cardiomyopathy in cattle [50] and mice [24]. 
Similar to some human ARVC subtypes including Naxos disease, cattle showed 
woolly hair and mice presented skin abnormalities. iASPP is also a key regulator 
of desmosomes and forms a ternary complex with desmoplakin and desmin. To 
explore why this defect caused cardiomyopathy, Notari et al. surveyed the 
distribution of iASPP in both human and mice [41], and detected expression at 
the cardiomyocyte ID in post-mortem human donors and in WT mice. They further 
showed that the presence of desmin, DSP, JUP and N-cadherin at the ID was 
strikingly decreased in iASPP-deficient mice when compared with WT 
specimens. However, the localization of β-catenin was preserved and co-
precipitation with specific antibodies demonstrated that iASPP interacted more 
directly with desmin and DSP and had minimal effect on the remaining 
desmosomal components. Cardiac magnetic resonance imaging in 12-week-old 
iASPP-deficient mice revealed biventricular dilation and systolic dysfunction and 
histological analysis revealed lipid droplets at the sites of fibrosis, which is 
consistent with an ARVC phenotype. Moreover, iASPP-deficient mice presented 
spontaneous non-sustained ventricular tachycardia (VT) and a lower median 
survival than WT littermates [41]. Cardiomyocytes of humans with ARVC were 
subsequently analyzed and showed reduction or even loss of iASPP in most of 
the cases, compared with controls. Given these findings, the authors suggested 
that mutations in the iASPP gene (PPP1R13L) may contribute to human ARVC; 
however, no pathogenic mutations have been reported to date in patients with 
ARVC. The main findings of each of the aforementioned ARVC mouse models 




Effects of exercise in ARVC animal models 
 
Competitive sports have been associated with a worse prognosis in patients with 
ARVC. When compared with inactive ARVC subjects or those who participate in 
recreational sports, athletes with ARVC were found to have a two-fold increased 
risk for ventricular tachyarrhythmia and death [47]. Furthermore, frequent and 
endurance exercise has been related to an increased likelihood of an ARVC 
diagnosis, ventricular arrhythmias and heart failure in desmosomal mutation 
carriers [26]. The mechanisms by which physical activity promotes disease 
progression, however, remain elusive. 
To investigate whether susceptibility to mechanical cardiac strain contributes to 
ARVC, Kirchhof et al. studied the effects of aging and exercise on heterozygous 
JUP-deficient mice [28]. At 10 months of age, all heterozygous mice had 
increased right ventricular volume, reduced right ventricular function, and 
increased spontaneous ventricular ectopy compared with WT littermates. 
Moreover, a subgroup of mice subjected to endurance training (swimming and 
running on a floating wheel) presented premature right ventricular dilatation and 
dysfunction at 5 to 6 months of age, whereas no changes were observed in the 
trained WT subgroup [28]. Additionally, heterozygous JUP-deficient mice 
presented a higher incidence of VT than WT mice at the age of 10 months, and 
this occurred 4 months earlier in trained specimens, indicating that endurance 
training accelerated the development of right ventricular dysfunction. As occurs 
in patients with ARVC, VT seems to originate from the RV in this model; however, 
unlike humans, no repolarization abnormalities were observed on ECG and no 
fibro-fatty replacement was found in the RV in these mice. Further analysis by 
the same group showed that myocardial concentration of connexin 43 was 
reduced in mutant mice, explaining the conduction slowing and VT inducibility 
due to an increase in re-entry substrate [15]. 
Using a transgenic cardiac-specific overexpression model of a desmoplakin 
mutation (DSP R2834H), Matherus et al. also observed accelerated cardiac 
remodeling in response to endurance exercise (daily running) [35]. Whereas 
cardiac function was preserved in all mice, mutant animals presented RV dilation 
and focal fat infiltration. All sedentary mice with DSP overexpression, both mutant 
and WT, showed an up-regulation of -catenin compared with non-transgenic 
littermates. Upon exercise, non-transgenic mice presented increased levels of 
nuclear and cytoplasmic -catenin, whereas cytoplasmic levels decreased in 
mice overexpressing the WT form of DSP and both nuclear and cytoplasmic 
levels decreased in mice overexpressing the R2834H DSP form. Furthermore, 
activation of GSK3-, a -catenin regulator, was seen only in mutant mice [35]. 
Overall, these results point to an impairment in Wnt/-catenin signaling in 
exercised mice expressing mutant DSP.  
DSP-cKO mice with specific homozygous loss of desmoplakin in cardiomyocytes, 
described earlier, recapitulate the postnatal disease features of a biventricular 
form of ARVC [31]. They also present increased susceptibility to exercise and 
catecholamine-induced arrhythmias, suggesting that exercise can exacerbate 
the ARVC phenotype, which is consistent with the aforementioned observations 
that ARVC is a common cause of sudden death especially in young athletes.  
The effect of endurance training on cardiac manifestations of ARVC has also 
been studied in a novel PKP2 R735X dominant-negative mouse model using 
adeno-associated virus gene delivery. Expression of the mutant protein was 
induced after a single adeno-associated virus type 9 injection [11] and endurance 
exercise training (swimming) was initiated 2 weeks later. After 10 months, trained 
but not sedentary mice developed RV dysfunction. Moreover, connexin 43 
presented an abnormal localization and a punctate distribution at the ID only in 
exercised-mutant mice. 
These results collectively show that murine models reproduce the association 
between endurance training and ARVC observed in humans: it worsens 
prognosis by an increased incidence of ventricular arrhythmias and cardiac 
dysfunction and it accelerates disease progression in healthy mutation carriers.  
 
Effect of therapies  
Current ARVC treatment is fundamentally palliative and is based on the 
prevention of SCD by implanting an ICD and on management of heart failure, 
including heart transplant. The main goals in the evaluation and management of 
ARVC are early diagnosis, SCD risk stratification, minimizing ventricular 
arrhythmias, and delaying the progression of disease. 
While ICD implantation represents a great advance in human ARVC treatment 
by preventing SCD [48], implants may cause clinical complications. Indeed, a 
study carried out on 610 ARVC patients with ICD showed that up to 20% of these 
individuals have complications, with the most frequent being the difficulty of 
electrode positioning (18.4%), followed by electrode dysfunction (9.8%), 
electrode shift (3.3%) and infection (1.4%) [48]. Furthermore, ICD focuses only 
on SCD prevention or treatment and does not consider the molecular 
mechanisms of the disease and its progression to heart failure. Thus, animal 
models represent an excellent tool to improve our understanding of the disease, 
to test existing therapies and to develop new pathophysiology-based therapies. 
Along this line, a heterozygous plakoglobin-deficient mouse model was used to 
test the usefulness of load-reducing therapy consisting of furosemide and nitrates 
[15]. Echocardiographic analysis revealed that therapy prevented the increase of 
the RV area and volume and normalized VT inducibility in JUP mutant mice, 
suggesting that load-reducing therapy prevents training-induced ARVC. 
Surprisingly, to the best of our knowledge, no other commonly used drug therapy 
such as ACE inhibitors or beta-blockers has been tested in ARVC animal models 
thus far.  
To generate a screenable model of AC, Asimaki et al. used the GAL4/UAS 
transactivation system to create a cardiac-specific transgenic zebrafish line 
overexpressing the human 2057del2 mutation in JUP [2]. Transgenic zebrafish 
developed mild bradycardia, decreased stroke volume and reduced cardiac 
output within 2 days of fertilization, and cardiomyopathy was fully penetrant at 4–
6 weeks, with cardiomegaly, cachexia and peripheral edema. Furthermore, 
mortality at 80 days was significantly higher in mutant zebrafish than in control 
animals (45% survival in mutants versus 77% in controls). The zebrafish model 
was used to test pharmacological suppressors of the disease phenotype by high-
throughput chemical screening. This search identified a GSK3β inhibitor 
(SB216763) that prevented heart failure and reduced mortality in this model [2]. 
The same authors tested SB216763 in a DSG2 mutant mouse model and initiated 
therapy from 3 weeks of age, before the onset of the disease. By 8 weeks of age, 
treated mutant mice presented a significantly higher LV ejection fraction than 
untreated mutants, which was similar to WT controls [8]. SB216763 therapy also 
prevented cardiac dysfunction in response to exercise in the same model. 
Animals were trained to swim from 5 to 16 weeks of age and treatment with 
SB216763 improved survival and LV function among mutants. In the same study, 
mice with a mutation in JUP were also treated with SB216763. Both DSG2 and 
JUP untreated mutants exhibited focal areas of fibrosis and inflammation that was 
absent in SB216763-treated equivalent mice. Furthermore, the abnormal 
localization of GSK3β at the ID in mutant mice was reversed by SB216763 
treatment [8] and translocated back to the cytoplasm, its normal location. The 
same authors showed that neonatal rat ventricular myocytes expressing a JUP 
or a PKP2 mutation normalized the distribution of ID proteins when GSK3β was 
knocked down. Together, these findings support the key role of aberrant GSK3β 
signaling in ARVC pathogenesis. Indeed, GSK3β inactivation has been shown to 
be beneficial in other pathological settings, including myocardial infarction [53], 
ischemia/reperfusion injury [39], and pressure overload [36]. 
 
Conclusions and future perspectives  
It is evident that results in animal models, while direct and robust (Table 2), still 
require complementary studies in human patients with ARVC. In the interim, it is 
important to characterize the effects of genetic mutations and to attempt to 
establish associations with clinical phenotypes. In the early stages of the disease, 
the “hidden phase”, patients are asymptomatic even if they are at high risk for 
ventricular arrhythmia and SCD. Thus, the identification of the first molecular 
events triggering the disease must be a major aim of future studies.  
Other inherited heart diseases, such as hypertrophic cardiomyopathy, have 
benefited from animal models to create new molecular therapies that are 
currently being used in clinical trials [22]. For example, viral-mediated gene 
therapy with calsequestrin-2 (CASQ2) in cardiomyocytes was found to improve 
cardiac function in a mouse model of catecholaminergic polymorphic ventricular 
tachycardia [12, 13]. The same authors subsequently showed that the 
administration of the CASQ2 gene restored the physiological function of 
calsequestrin-2 protein in human induced pluripotent stem cells derived from 
patients [30]. These results pave the way for individualized genetic therapies in 
cardiomyopathies, including ARVC.   
To date, the GSK3β inhibitor SB216763 is the only molecule that has been shown 
to change the course of disease in murine models by enhancing β-catenin 
signaling. It was initially discovered via chemical drug screening in a zebrafish 
model, which may represent a powerful model for future ARVC drug research 
and should be further explored. The Wnt/-catenin pathway appears to have a 
central role in the pathogenesis of ARVC and is a key regulator of myogenesis 
versus adipogenesisis. As it is specifically blunted in ARVC patients and mouse 
models, reduced Wnt/-catenin signaling leads to enhanced adipogenesis, a 
characteristic feature of ARVC. These emerging concepts need be explored in 
depth in future research. In this regard, recent data on microRNA profiling in 
ARVC using functional enrichment analysis have shown a correlation between 
miR-21-5p and miR-135b and the Wnt pathway [55]. Of interest, these 
microRNAs also target Hippo signaling, which interacts with the Wnt/β-catenin 
pathway and whose pathogenic activation leads to enhanced adipogenesis in 
ARVC [9]. These findings may guide the search for new microRNA-based 
therapeutic targets to modify Wnt/-catenin and Hippo signaling to improve the 
outcome of ARVC. 
Finally, while ARVC is mainly a disease of desmosomal proteins, future research 
should explore mechanisms beyond the desmosome that may lead to the 
identification of curative therapies that target specific pathogenic pathways. 
Although it is evident that certain aspects of human ARVC remain to be 
demonstrated in animal models (Figure 1), they represent the best available tools 
to improve our knowledge of the pathophysiology of human disease and explore 
the best strategy for effective treatment. Additionally, animal models have shed 
light on some other relevant issues, such as the effect of physical activity on 
accelerating disease progression. These findings are very important for clinically 
unaffected mutation carriers, as they confirm what has been already observed in 
clinical practice. 
Future research should take into account that many murine models are currently 
available, that they are reproducible and offer promising therapeutic solutions. An 
example of this are the β-catenin activators that have demonstrated a central role 













ARVC1 TGF3 14q24.3      





ARVC3 Unknown 14q12-q22      
ARVC4 TTN 2q32.1-
q32.3 





ARVC5 TMEM43 3p25.1      
ARVC6 Unknown 10p14-p12      
ARVC7 DES 2q35     Can cause DCM 
or RCM  





[31, 35] [41]  
ARVC9 PKP2 12p11  [7, 23] [11]   
ARVC10 DSG2 18q12.1  [14, 27, 
43, 45] 
[8] [8]  
ARVC11 DSC2 18q12.1  [6, 37]    
ARVC12 JUP 17q21.2 Naxos 
disease 
[3, 4, 9, 
29, 46, 
56] 
[15, 28] [8, 15, 56]  
 
Table 1. Type, causative mutated gene and gene location associated with 
human ARVC. DES: desmin; DSC2: desmocollin 2; DSG2: desmoglein 2; DSP: 
desmoplakin; DCM: dilated cardiomyopathy; JUP: junction plakoglobin; RCM: 
restrictive cardiomyopathy; RYR2: ryanodine receptor 2; TTN: titin; TGF3: 
transforming growth factor beta 3; TMEM43: transmembrane protein 43; PKP2: 
plakophilin 2. References are listed for the mouse model as well as for the effect 
of exercise in the model and/or a treatment tested. There are no murine models 




Protein Gene mutation / 
defect 
What have we learned? Reference 
Desmoplakin DSP-null • Early embryonic lethality [16] 
DSPR2834H point 
mutation 
• JUP is mislocalized to the nucleus 
• Interruption of DSP-desmin interaction at 
intercalated discs  
• Increased cardiomyocyte apoptosis, 
cardiac fibrosis, and lipid accumulation 
• Ventricular enlargement and cardiac 
dysfunction in both ventricles 
[54] 
DSP+/- • Reduced expression of desmoplakin 
leading to connexin mislocalization 
• Alterations in conduction-repolarization 




• Downregulation of connexin 43 
• Wnt/-catenin signaling pathway is 
unimpaired 
• Ventricular arrhythmias exacerbated by 
exercise and cathecolamines 
[31] 
Exons 4-5 deletion • Cardiomyopathy develops by 8 weeks of 
age 
• Absence of DSG2 protein by 16 weeks of 
age 
• Abnormal JUP and connexin 43 at myocyte 
junctions 
• SB216763 prevents cardiac dysfunction 
and fibrosis 
[8] 
Plakophilin 2 PKP2 null • Decreased association of cardiac junctional 
plaques with DSP, JUP and desmosomal 
cadherins 
• -catenin and JUP remain in their correct 
locations 
• Heart rupture during cardiac development 
[23] 
 PKP2+/- • Myocyte sodium current defects  
• No histological or anatomical differences 
versus controls 
[7] 





• Necrosis, inflammatory response and 
myocardial calcification  
• No fatty infiltration 
• Ventricular arrhythmias and sudden death 




• In vivo interaction between DSG2 and 
Na(V)1.5 
• Electrical instability before structural 




• Space widening in ID and reduction in 
action potential 
• Compromised adhesion of cardiomyocytes 
[27] 
Desmocollin 2 miR-130a 
overexpression 
• miR-130a represses 80% of DSC2 
translation in the myocardium 
• Biventricular fibrosis and lipid accumulation 
• Right ventricular dilation, premature 
ventricular complexes 
[37] 
 DSC2 cardiac 
overexpression 
• Biventricular dysfunction 
• Cardiac fibrosis, necrosis and calcification 
• Early inflammatory and fibrotic remodeling 
pathways up-regulated 
[6] 
Plakoglobin JUP null • Embryonic lethality between days 12 and 
16 
[46] 
 JUP null • Embryonic lethality from embryonic day 
10.5 onward; some died around birth 
• Partially compensatory mechanisms for 
JUP and β-catenin 
• JUP translocates to the nucleus  
[3] 
• Suppression of the Wnt/-catenin signaling 
pathway 
• Enhanced adipogenesis 
 JUP cardiomyocyte-
specific KO 
• Cardiomyopathy develops by 6–8 weeks of 
age 
• Loss of cardiac myocytes, inflammatory 
infiltration, fibrous tissue replacement and 
cardiac dysfunction 
• No spontaneous or induced arrhythmias 
[29] 
 Cardiac specific 
truncated JUP 
(Myh6:JUP) 
• Suppression of the Wnt/-catenin signaling 
pathway 
• Pathogenic activation of the Hippo pathway 
• Enhanced adipogenesis 
[9] 
 JUP2157del2 mutation • Focal areas of inflammation and increased 
cardiomyocyte apoptosis 
• Reduced JUP signal at intercalated disks 







• Fibrosis limited to the right ventricle, no fat 
infiltration 








iASPP deficiency • iASPP interacts with DES and DSP, with 
minimal effects on other desmosomal 
components  
• Preserved β-catenin localization 
• Biventricular dilation and systolic 
dysfunction by 12 weeks of age 
[41] 
 




Figure 1. Achievements to date in ARVC research and medical management 
(left) and what remains to be addressed to reach an effective therapy to cure the 
disease (right). 
Figure 2. Desmosomes and signaling pathways implicated to date in the 
progression of ARVC. Activating (black) and inactivating (red) phosphorylations.  
IS: intercellular space; PM: plasma membrane; -cat: -catenin; desmin (medium 
green); DSC2: desmocollin 2 (blue); DSG2: desmoglein 2 (red); DSP: 
desmoplakin (yellow); Frz: Frizzled receptor; JUP: junction plakoglobin (light 
grey); PKP2: plakophilin 2 (dark grey); TCF/LEF: T-cell factor/lymphoid enhancer 
factor.   
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